These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16669979)

  • 1. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity.
    Al-Aly Z; Sachdeva A; Philoctete Ashley JM; Bastani B
    Nephrology (Carlton); 2006 Apr; 11(2):151-5. PubMed ID: 16669979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil.
    Tedoriya T; Keogh AM; Kusano K; Savdie E; Hayward C; Spratt PM; Wilson M; Macdonald PS
    J Heart Lung Transplant; 2002 Sep; 21(9):976-82. PubMed ID: 12231368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity.
    Filler G; Gellermann J; Zimmering M; Mai I
    Transpl Int; 2000; 13(3):201-6. PubMed ID: 10935703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients.
    Hamour IM; Lyster HS; Burke MM; Rose ML; Banner NR
    Transplantation; 2007 Mar; 83(5):570-6. PubMed ID: 17353776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report.
    Ducloux D; Fournier V; Bresson-Vautrin C; Rebibou JM; Billerey C; Saint-Hillier Y; Chalopin JM
    Transplantation; 1998 Jun; 65(11):1504-6. PubMed ID: 9645813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
    Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
    Aleksic I; Baryalei M; Busch T; Pieske B; Schorn B; Strauch J; Sîrbu H; Dalichau H
    Transplantation; 2000 Apr; 69(8):1586-90. PubMed ID: 10836367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.
    Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS
    Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of mycophenolate mofetil in patients with a transplanted kidney and cyclosporin nephrotoxicity].
    Hrvacević R; Ignjatović Lj; Vavić N; Dimitrijević J; Drasković-Pavlović B; Dujić A; Elaković D; Kronja G; Marić M
    Vojnosanit Pregl; 2001; 58(2):157-60. PubMed ID: 11475669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
    Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine.
    Baryalei M; Zenker D; Pieske B; Tondo K; Dalichau H; Aleksic I
    Transplant Proc; 2003 Jun; 35(4):1539-42. PubMed ID: 12826215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.